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Infections with human papilloma viruses (HPV) are the most prevalent sexually transmitted 
diseases. The vast majority of the sexually active population acquires them during lifetime but 
almost all HPV infections become resolved within a year. A small fraction of infections persists 
and can lead to cervical lesions, which may progress to cancer and their appearance is 
controlled by long-established cervical screening programs. Since licensure of the first HPV 
vaccines almost 15 years ago, more than one hundred countries introduced HPV vaccination 
into their national immunization strategies in order to prevent cervical cancer development. 
Despite permanent evaluation of immunological, virological and clinical endpoints of vaccine 
effectiveness, the antibody dynamics and protection are not fully understood, which is 
particularly true after natural infection. We thus studied humoral immune responses after 
natural infection and vaccination. In addition, we investigated reasons for rare events of 
cervical lesion development after immunization.  
In studies of serological responses to HPV infections (papers I and II) we demonstrated that 
the characteristics of type-specific anti-HPV antibodies to the most common oncogenic types 
(HPV 16 and 18) apply also to the other high-risk HPVs. Serum antibodies were generally 
stable over time and were strongly associated with cervical HPV DNA positivity. Seropositivity 
to multiple anogenital HPV types was also associated with presence of HPV DNA and we 
observed an association with an abnormal cytology and with the presence of non-genital 
HPVs. The latter finding suggests that a definite subset of women is more likely to seroconvert 
to multiple HPV types, which could be true also in induction of antibody responses to HPV 
vaccines.  
Our serology assay was validated using HPV DNA from serially collected cervical samples as a 
standard. This was shown to be a valuable approach for evaluation of assay performance since 
repeated sampling for transient exposure may improve sensitivity without impairing 
specificity. In consequence, our multiplexed HPV serology assay was expected to be useful in 
studies of immune responses to HPV infection and vaccines. 
Our research on immunogenicity of the HPV vaccines was a head-to-head comparison of the 
anti-HPV antibody responses between the quadrivalent Gardasil and bivalent Cervarix (papers 
III and IV). We evaluated the sustainability of vaccine-targeted and cross-reactive serological 
responses up to 12 years post-vaccination. We found that the antibody levels induced by 
Cervarix were stable and virtually all women had anti-HPV antibody titers above those 
induced by HPV infection. In contrast, most of the recipients of quadrivalent Gardasil had 
detectable antibody levels but 8 % (HPV-16) and 18 % (HPV-18) showed a titer-decline to 
below the natural infection antibody level. Comparison of the antibody responses exhibited 
that the anti-HPV-16 antibody levels were 5.1-fold higher and anti-HPV-18 were 18.4-fold 
higher in the recipients of bivalent Cervarix (p < 0.0001). Further, the seropositivity to most 
of the non-vaccine HPV types was more prevalent among the women vaccinated with 
Cervarix than with the Gardasil. Nonetheless, anti-HPV antibody levels and avidity were 
comparable for almost all HPV types. For both vaccines, we found that the seroprevalence to 
cross-reactive types (HPV-31, -33, -35, -45, -52, -58, -59, -68 and -73) increased with the anti-
HPV-16 levels. In the recipients of the bivalent HPV vaccine, antibody levels of the non-vaccine 
types HPV-31, -35, -51, -52, -56 and -58 increased with the anti-HPV-16 levels, which was not 
observed in women vaccinated with the Gardasil. Furthermore, our investigations showed 
that anti-HPV antibody levels shortly after vaccination predicted antibody levels and antibody 
avidity a decade later. 
Lastly, we investigated whether the development of cervical lesions after HPV vaccination 
is associated with the vaccine-targeted HPV types (paper V). In this research project, we 
studied a cohort of women immunized with HPV vaccine before 17 years of age. We observed 
that not a single woman was positive for the low-risk vaccine types HPV-6 and -11. We found 
that cervical lesions were usually not associated with the vaccine-targeted HPV types of the 
highest oncogenic risk. Instead, non-vaccine types having a lower potential for inducing 
progression to cervical cancer were more likely to be present. Evidently, the latter finding has 
significant implications for the future design of cervical screening strategies that would target 
highly vaccinated cohorts of women and for design of surveillance and monitoring strategies. 
Another consequence of these findings is the information to physicians and vaccinated 
women that cervical dysplasia may occur despite HPV vaccination but likely caused by HPV 
types that rarely progress to cancer.  
In summary, the findings presented in this thesis contribute to the understanding of the 
dynamics and the durability of naturally acquired and vaccine-induced antibody responses to 
HPV. The results give reasons for the cervical lesion-development among young HPV-
vaccinated women. We conclude that the future definition of a clinically relevant anti-HPV 
antibody protective threshold, as well as the evaluation of determinants for higher and 
broader immunological responses to HPV vaccines are necessary to optimize HPV vaccine 
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1.1 HPV AS A CAUSATIVE AGENT OF HUMAN CANCERS 
Human papillomaviruses (HPVs) are small non-enveloped DNA viruses, which infect human 
epithelial cells. In some cases they escape from the host immune surveillance, persist in basal 
keratinocytes over long periods of time and, rarely, cause malignant diseases at different 
anatomical sites, most notably in cervix [1]. In 1983, the first laboratory evidence suggested 
a causative link between HPV16 infection and cancer stating that “the regular presence of 
HPV DNA in genital cancer biopsy samples does not per se prove an etiological involvement 
of these virus infections, although the apparent cancer specificity of HPV16 is suggestive of 
such a role”. This observation shifted focus from the Herpes Simplex Virus, which was the 
main suspect causing genital cancers [2] to the rapidly growing family of human 
papillomaviruses. Accumulated numerous biological and epidemiological evidences fulfilled 
Hill’s criteria for establishing a causal relationship between HPV infection and a subset of 
human genital and oropharyngeal cancers [3].  
The International Agency for Research on Cancer classified genital HPV types 16, 18, 31, 33, 
35, 39, 45, 51, 52, 56, 58 and 59 as carcinogenic, and HPV 68 as probably carcinogenic to 
humans [3]. These HPV types are also frequently referred to as high-risk HPV (HR-HPV). 
Similarly, HPV types which do not associate with human cancers are called low-risk (LR-HPV), 
comprising HPV 6, 11, and others. HPV 6 and 11 usually cause only benign epithelial diseases, 
such as anogenital warts and recurrent respiratory papillomatosis [4].  
Invasive cervical cancers rank the fourth most common cancers in women worldwide leading 
to an estimated half a million new cases per year [5,6]. Recent estimates demonstrate that 
practically 100 % of cervical cancer cases, 88 % of anal, 78 % of vaginal, 50 % of penile, 25 % 
of vulvar and 31 % of oropharyngeal carcinomas are attributable to infection with HPV [5]. 
The total burden of HPV-associated cancers is translated into 570,000 - 620,000 new cases 
per year in women and 60,000 - 70,000 cases in men [7,8]. Exemplified for female population, 
the geographical distribution of proportions of cancer cases attributable to infections with 
HPVs in 2018 are shown in Fig. 1 [8,9]. Age-standardized incidence rates of these HPV-
associated cancers are inversely associated with the national income levels of the countries, 
highlighting that cervical cancer screening and HPV vaccination programs in low-income 
countries have a huge preventive potential [8].  
1.1.1 Human papillomaviruses in all their phylogenetic beauty 
Viruses of papillomaviridae family exhibit a strong host- and cell-type tropism, infecting basal 
epithelial cells of a wide range of vertebrates, including humans [10]. By the degree of 
nucleotide sequence homology of the most conserved L1 gene, HPVs are classified into 
genera, species and types [11]. HPVs from different genera share 45 – 60 % similarity of L1 
sequence, within a genus (species) – between 60 and 70 % [11]. A novel HPV type has less 
than 90 % similarity to any other HPV type [12]. Beyond type, homology between 90 % and 




Figure 1. HPV infection population attributable fraction (PAF, %) for all cancer cases among females, 2018 [8]. 
The boundaries and names shown and the designations used on this map do not imply the expression of any 
opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, 
territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted 
and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. 
Data visualization (adapted): IARC / GCO, World Health Organization [9]. 
Established by the International Committee on Taxonomy of Viruses (ICTV), the five known 
HPV genera are marked by Greek letters (Alpha-, Beta-, Gamma-, Mu- and Nu papillomavirus) 
[13]. Except of Alpha papillomaviruses, all of genera are mainly associated with cutaneous 
infections [1]. On the lower order of classification, species naming is formed by the name of 
genera which is followed by an integer, e.g. Alpha-9 [11]. HPV types are assigned their names 
(e.g., HPV 16) by the International HPV Reference Center [12,14] and the unique numbers are 
based on the numerical order of their discovery. To date, at least 226 types of HPV are 
identified, cloned and stored in the human papillomavirus reference center [12].  
1.1.2 Virus structure and lifecycle  
HPV is a non-enveloped icosahedral virus of about 55 nm in diameter [10]. The life cycle of 
HPV is confined to epithelial cells, with replication occurring only in fully differentiating 
squamous keratinocytes [15]. The viral genome consists of about 8 kbps of double-stranded 
circular DNA comprising coding and non-coding regions (Fig. 2) [1]. The latter consists of the 
upstream regulatory region (URR), which is a sequence of regulatory elements controlling 
early gene transcription and replication [15,16]. The coding regions are separated in two 
classes of viral genes encoding early (E1, E2, E4, E5, E6, E7) and late (L1 and L2) proteins. 
Early events of the viral life cycle depend on the accessibility of the basement epithelial 
membrane and of basal keratinocytes, that may become exposed upon micro-wounding or 
abrasion [17]. The viral capsid requires contact with heparin sulphate proteoglycans [18], 
followed by furin cleavage of L2 capsid protein resulting in structural changes of the capsid 
[19]. Interactions with secondary cellular receptors such as annexin A2 [20,21], growth factor 
receptors [18], CD151 (a member of the transmembrane 4 superfamily) [22,23] allow cell 
entry by endocytosis [24], and subsequent release into the cytoplasm. Entry of the viral DNA 
into the nucleus – which is a prerequisite for replication – occurs during nuclear envelope 





Figure 2. Genomic organization of a typical mucosal high-risk HPV and main functions of the proteins encoded 
by viral early and late genes [15]. HPV, human papillomavirus; URR, upstream regulatory region; viral ORI, viral 
origin of replication; E1-7, genes encoding early viral proteins; L1-2, genes encoding late viral proteins. Early 
genes are transcribed in the lower layers of epithelia and late genes – in the upper. Adapted from M. Stanley, 
Epithelial Cell Responses to Infection with Human Papillomavirus, Clin Microbiol Rev Apr 2012, 25 (2) 215-222, 
reproduced with permission from the American Society for Microbiology, RightsLink Copyright Clearance 
Center. 
Once HPV successfully infected the keratinocytes, its life cycle becomes aligned with the 
stages of epithelial differentiation: genome maintenance (basal cells), viral protein production 
(suprabasal layers of epithelia), followed by virion assembly and release (upper layers of 
skins/mucosa) (Fig. 3) [26]. During maintenance, early proteins E1 and E2 control viral 
genome replication and episome maintenance. In the following stages of the lifecycle, 
proteins E4 and E5 support virus release by disrupting cytokeratin structure and contribute to 
genome amplification, respectively [27]. Products of E5 gene expression also interact with 
epidermal growth factor receptors, mediate immune evasion and induce koilocyte formation 
[1,27,28]. Major (L1) and minor (L2) capsid proteins package the genome and, after 
intracellular maturation, newly created virions are ready for shedding [1,16]. 
However, in HR HPV types, E6 and E7 may also be expressed in early stages, inducing basal 
cell proliferation [1,16]. Deregulation of E6 and E7 expression leads to binding and 
degradation of tumour suppressor proteins p53 and pRb, respectively. Impaired functionality 
of p53 in turn results in inhibition of apoptosis; absence of pRb induces genome instability 
and cell cycle entry. 
1.1.3 Persistence of HPV infection and disease progression 
Worldwide, HPV infections are the most common among sexually transmitted infections and 
a large proportion of the sexually active population acquires such HPV infection(s) during 
lifetime [29]. Epidemiological evidence suggests that within three years from sexual debut up 
to 44 % of adolescent girls become HPV DNA positive to at least one of the eight HPV types 
(HPV 6, 11, 16, 18, 31, 33, 52, 58) [30]. However, most women clear HPV infections within 





Figure 3. Scheme of the course of progression of HPV infection to cervical cancer [32]. Basal epithelial cells rest 
on the basement membrane above dermis. Human papillomavirus (HPV) access these cells through micro-
wounds. During the early stages of infection, the HPV genes E1, E2, E5, E6 and E7 are expressed, which 
maintains viral DNA replication from the episomes (purple nuclei). As epithelial cells differentiate, in the upper 
layers the viral genome is further replicated, and genes E4, L1 and L2 are expressed. Products of expression of 
late genes (L1 and L2) encapsidate the viral genomes to form progeny virions in the nucleus, which leave the 
cell upon its death and can then initiate a new infection. Low-grade intraepithelial lesions support viral 
replication. Persistent infections with high-risk HPV types may progress to high-grade cervical intraepithelial 
neoplasia, microinvasive and invasive cancer and is associated with the integration of the HPV genome into the 
host chromosomes (red nuclei), loss or disruption of E2, upregulation of E6 and E7 oncogene expression. 
Adapted from Woodman, C., Collins, S. & Young, L. The natural history of cervical HPV infection: unresolved 
issues. Nat Rev Cancer 7, 11–22 (2007), reproduced with permission from the Springer Nature, RightsLink 
Copyright Clearance Center. 
Time of HPV infection clearance varies between geographical regions and may depend on a 
number of biological and behavioral determinants, such as the type of HPV, the viral load, 
previous HPV infections, co-infection with high-risk HPV type, HIV status, site of infection, 
number of sex partners, etc. [31,33–37]. The HPV type-dependent time to clearance was 
demonstrated in an early study of the natural history of cervical HPV infections: the estimated 
time of HPV clearance in HPV DNA-positive girls after adolescence was c. 10 months for HPV-
16 and almost 8 months for HPV-18 [30]. According to a meta-analysis, these intervals are 
longer, reaching on average a year for HPV-16 and almost ten months for HPV-18, with no 
distinguishable trend of HPV persistence by age [31].  
Persistent infection with HR HPV types is a main factor determining progression to cervical 
cancer, and several co-factors may contribute to it. As reviewed by the IARC working group 
on human carcinogens, the co-factors for infection persistence and progression to cervical 
lesions include cigarette smoking, number of pregnancies, immunosuppression and exposure 
to other infectious agents [3]. Evidence for the other co-factors, such as the use of hormonal 
contraceptives, exposure to certain nutrients (e.g., folate), as well as genetic determinants, 
are not consistent across the studies [3].  
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Once HPV infection cannot be cleared and persists for a year or more, the risks for malignant 
transformation increase [30,38,39]. Cervical lesion development towards cancer undergoes 
three consecutive stages of malignant disease precursors called cervical intraepithelial 
neoplasia (CIN) of grades 1-3 (Fig. 3) [32]. When the neoplasia grade increases, the probability 
for persistence and progression towards the next grade and towards cervical cancer becomes 
also higher [39]. Inversely, the probability of lesion regression decreases over the course of 
neoplastic development, ranging between 40 % for the CIN 2 and 33 % for the CIN 3 lesions 
[39,40]. The course of disease progression is reflected by the classification of cervical 
epithelial cell abnormalities (Bethesda classification) used in clinical practice:  
- low grade squamous intraepitelial lesions (LSIL), which encompass cytological changes 
that correspond to HPV infection/mild dysplasia/CIN1; 
- high grade squamous intraepithelial lesions (HSIL), which encompass moderate and 
severe dysplasia, CIS (carcinoma in situ), CIN 2 and CIN 3, and, if invasion is suspected, 
may have features of invasion; 
- squamous cell carcinoma [41].  
A six-months persistent infection with HR HPV types is associated with highly elevated risks 
for development of precancerous lesions and cervical cancer [35,36,42]. Baseline presence of 
HPV-16/-18 DNA confers 8.5-fold and 18.6-fold increased risks of cervical cancer in situ and 
invasive squamous cell carcinoma, respectively, compared to HPV DNA negative women [42]. 
This observation is consistent with the findings that HPV-16 and -18 are the most abundant 
papillomavirus types in cervical cancers, accounting for about 70-75 % of all invasive cervical 
cancer (ICC) cases [3]. In the remaining 25-30 % of cervical cancer biopsies, the descending 
prevalence of HPV types is: HPV-33,-45,-31,-58,-52,-35,-59,-51,-56,-39,-68 [3].  
Overall, HPV-16 is one of the most persistent, as well as the most frequent type in cervical, 
anal, vulvar and vaginal lesions [31,35]. The proportion of HPV-16 DNA positivity in cervical 
sample of HPV-positive women increases with the augmentation of severity of cytological and 
histological findings, being around 20 % in normal cytology and atypical squamous cells of 
undetermined significance, 25 % in low-, 48 % in high-grade squamous intraepithelial lesions, 
and 63 % in the ICC biopsies [43]. A similar trend was observed for the frequency of HPV DNA 
integration into the host chromatin, which increases with cervical disease severity [1,32]. 
It appears, however, that the subset of cervical cancers it too heterogeneous for referring to 
as a single disease and the risk for cancer development is not only HPV type-dependent but 
is related to the origin/location of the initially infected cervical cells (basal cells of the 
ectocervix versus cuboidal cells at the squamo-columnar junction vs columnar cells of the 
endocervix) [44]. In particular, the origin of the infected basal cells has recently been 
suggested to be one of the major determinants for the speed of cervical lesion progression 
but more research is needed to elucidate underlying mechanisms [44]. 
1.2 IMMUNE RESPONSE TO HPV  
The immune system controls HPV infection by both innate and adaptive answers of the 
immune system (Fig. 4) [45]. It responds to HPV infection by initiating the innate chain after 
detection of damage or by TLR-mediated sensing the pathogen-associated molecular patterns 
(TLR1, TLR3, TLR7, TLR8, TLR9, as well as TLR2) [15,46–48]. At this stage, immediate non-
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specific effectors are activated, and type I INF-ɑ and-β are secreted. Then, proinflammatory 
cytokines and chemokines support activation of local antigen presenting (APC) Langerhans’ 
cells which bring the processed viral fragments to locoregional lymph nodes. Subsequent 
activation of CD8 cytotoxic T cells and antibody-secreting B-cells is mediated by T helper cells 
(Fig. 4). Cellular immunity clears HPV infection from the infected sites and humoral chain of 
adaptive immunity generates neutralizing mucosal antibodies which prevent HPV infection in 
future [45].  
 
Figure 4. Scheme of main steps in natural immune control of HPV infection [17,45]. (1) Innate immune system 
recognizes damage of epithelium. (2) Immediate non-specific effectors are activated, and interferons are 
secreted. (3) Proinflammatory molecules promote activation of Langerhans’ cells, processing of the antigen and 
migration to locoregional lymph nodes, which further (4) activates the adaptive chain of immunity. Specific CD4 
T helper 1 type immunity supports development of effector and memory CD8 cytotoxic T cells against early 
viral proteins. (5) In addition, T helper cells also support activation of B cells that secrete neutralizing 
antibodies. Long lived plasma cells produce high levels of antibodies against HPV. These antibodies transudate 
into the mucosa and protect against re-infection (6). Reproduced from Stern P.L., Einstein M.H. (2012) The 
Immunobiology of Human Papillomavirus Associated Oncogenesis. In: Borruto F., De Ridder M. (eds) HPV and 
Cervical Cancer. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-1988-4_3, with permission from 
the Springer Nature, RightsLink Copyright Clearance Center. 
HPV developed passive and active ways for evading host’s immune system [45,49]. Examples 
for passive immune escapes are: i) absence of viremia and thus no widespread infection, ii) 
no lytic replication step, and no inflammation. In addition, iii) rare codons result in low level 
viral protein expression, and iv) by the time virions are shedding on upper layer of the 
epithelium, they are not accessible for immune cells anymore [45,49]. Recently, another, 
novel humoral immune escape mechanism through seroconversion to L1 isoforms of 
different length, was described [50]. 
Active ways to escape the immune response are mainly carried through hampering IRF, IFN 
and NF-kB signaling through the early HPV proteins E2, E5, E6 and E7, as well as through 
impairing antigen presentation by absence of activation/recruitment/sustainment of antigen 
presenting cells (E5 and E7) [15,49,51].  
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1.2.1 Naturally acquired anti-HPV antibody responses  
The ability to evade from the recognition by the immune system at least partially explain why 
about 40 % of HPV-16 infections in females do not result in seroconversion [52]. Among those 
who become seropositive, it may take up to 1.5 years to mount measurable antibody 
responses [52], which are usually stable over time [53–55]. Compared to transient HPV 
infections, persistent are more likely to induce seroconversion [56]. Evidence from the case-
control study shows that anti-HPV antibodies to HR types 16 and 18 are associated with the 
higher odds for development of cervical cancer [57]. Potential protectivity by the naturally 
acquired immunity against the incident and persistent infections appears to be inconsistent 
across the HPV types and across the studies [58–61]. However, meta-analysis demonstrated 
significant protection against subsequent infection with HPV-16 (pooled RR, 0.65; 95 % CI 
0.50–0.80) and HPV-18 (0.70; 0.43–0.98) in women [62].  
HPV type-specific seroconversion is a slow process: subjects with an incident HPV-16 infection 
seroconvert to IgG within 8.3 months (maximum of 56.7 % positivity) and to IgA within 14 
month (maximum of 37.0 % positivity) [63]. Acquisition of anti-HPV antibodies is associated 
with HPV DNA positivity (same-type or the phylogenetically related genotypes), with 
persistence of HPV infection and with higher viral load [63]. Seroepidemiological features of 
HPV-16/18-infections were extensively studied but less is known about the other HR HPV 
types [53,64–66]. Genotype-specific estimates of the association between seropositivity and 
HPV infections are scarce, inconsistent across the assays, and vary between the different HPV 
types even when the same method is used [67–71]. For instance, in multiplex serology assay 
based on glutathione S-transferase fusion protein, type-specific agreement of HPV DNA 
positivity and seropositivity was observed for HPV-33, -52 and 58 but not for HPV-16, -18, -31 
and -45 [68].  
1.2.2 Humoral immune responses to VLP-based HPV vaccines 
Quadrivalent Gardasil (HPV-6, -11, -16, -18; Merck &Co, Kenilworth, NJ, USA/Sanofi Pasteur 
MSD, Lyon, France) and bivalent Cervarix (HPV-16, -18; GlaxoSmithKline Biologicals, Wavre, 
Belgium) vaccines were licensed almost 15 years ago. In a more recent nonavalent Gardasil, 
additional five HR types HPV-31, -33, -45, -52, -58, as well as higher amounts of adjuvant and 
antigens, are included.  
All these vaccines are based on virus-like particles (VLPs), which use the property of 
spontaneous self-assembly of L1 proteins after their overexpression in mammalian- and in 
insect cells (Cervarix) or in yeast (Gardasil). Aside of the included HPV types, the 
abovementioned vaccines also differ in their adjuvants, which are aluminiumhydroxide and 
phosphorylipid AS04 in Cervarix and aluminiumhydroxy-diphosphosulfate in Gardasil.  
Evidently, each of the three licensed HPV VLP-based vaccines is safe and immunogenic [72–
77]. Comparison of the two Gardasil vaccines showed that antibody levels to HPV-6, -11, -16, 
and -18 in the nonavalent vaccine recipients are non-inferior to those of the quadrivalent 
vaccine recipients (QVR) up to three years after vaccination [77]. Vaccine efficacy (VE) was 
demonstrated against incident and persistent HPV infections, as well as genital warts 




VLP-based HPV vaccines induce high levels of high-avidity antibodies with neutralizing 
properties [77,91–93], which transudate to the mucosal surfaces. By blocking different viral 
surface epitopes, these antibodies prevent HPV from interaction with the membrane 
receptors and from binding to the cells [94–96]. This mechanism of viral epitope blocking was 
demonstrated in in vitro neutralization assays [97–99], in the murine genital-challenge model 
using passive transfer of neutralizing antibodies[100], and among the HPV vaccine recipients 
by comparing systemic anti-HPV antibody levels with local in the cervicovaginal secretions 
[91,94,101,102]. Both in the BVR and in the QVR, systemic and mucosal antibody levels 
correlate strongly (R2 for HPV-16 = 0.73 - 0.97; HPV-18 = 0.69 - 0.96). Notably, also for the 
non-vaccine HPV types, antibody concentrations in the cervicovaginal secretions correlate 
with the serum levels (R2 for HPV-31 = 0.84; HPV-45 = 0.71) [91]. 
HPV vaccines induce long-lasting cellular and humoral responses: the presence of reactive 
memory B cells was demonstrated by an antigen challenge with the quadrivalent vaccine five 
years after the initial three-dose immunization [103]. It yielded a fast and strong humoral 
response: one week after the booster dose, antibody levels reached titers observed one 
month after the initial full-dose vaccination. One month post-challenge, anti-HPV antibody 
levels exceed those obtained after the three-dose immunization [103]. At least up to ten years 
from immunization, post-vaccination antibody responses to HPV remain above levels 
acquired after infection [92,104–110].  
Cross-protective VE against phylogenetically related non-vaccine genotypes was 
demonstrated for the bivalent and the quadrivalent HPV vaccines, although it has been 
weaker than VE against HPV-16/-18 [78,84,85,111]. The evidence for cross-protection is more 
consistent among the bivalent vaccine recipients (BVR) than the QVR [81,83,85–90,112–114]. 
In line with this, evidence from the HPV vaccine immunogenicity studies demonstrates that 
Cervarix induce higher antibody levels than the quadrivalent Gardasil [91,101,110,115,116]. 
In the short-term vaccine comparison studies, neutralizing anti-HPV antibody levels of 
vaccine-targeted HPV-16 and -18, as well as non-targeted HPV-31, -33-, 35, -45, -52, -58, were 
higher in the BVR than in the QVR [91,117]. Scarce data from the long follow-up studies 
further reported higher seroprevalences to HPV-31 and -45 in the BVR than in the QVR [118]. 
Collectively, sustainable cross-reactive immune responses against HPV-31,-33,-45,-52,-58 
were reported for the bivalent HPV vaccine [105,119], however among the QVR it was 
applicable mainly for HPV-31 [120,121]. The major drawbacks in cross-reactive 
immunogenicity studies of the HPV vaccines are their relatively short time of follow-up and a 
limited number of HPV types under evaluation [118,122,123].  
HPV vaccine-induced serological responses which are typically 10 - 100 times higher than the 
antibody levels after HPV infection (Fig. 5) [124–127]. This was demonstrated for the single- 
double- and triple-dose immunization schedules [125,127] and the results from the 
randomized clinical vaccine trials [128–130] prompted WHO to update the recommendations 
of HPV vaccination schedules towards the two-dose regimen. This is currently adopted in 
many organized immunization programs, although vaccination of the immunocompromised 
follows a three-dose schedule [131]. In addition, since anti-HPV antibody responses in the 
group of older females (age ≥ 15 years) were demonstrated to be lower compared to the girls 
vaccinated at younger age [94,132], vaccine recipients of more than 15 years of age should 




Figure 5. HPV-16 virus-like particle antibody geometric means induced by the bivalent vaccine in 18–25 years 
old women enrolled to the Costa Rica clinical trial [127,133]. Three-dose immunization was performed at 
months 0, 1, and 6; two-dose – at months 0 and 6; single-dose – at month 0. HPV, human papillomavirus. 
Timeline of vaccination is marked with asterisks [127,133]. Reproduced from Schiller JT, Müller M. Next 
generation prophylactic human papillomavirus vaccines. The Lancet Oncology. 2015; 16(5):e217–e225, with 
permission from the Elsevier, RightsLink Copyright Clearance Center. 
A post-hoc analysis of the Costa Rica HPV Vaccine trial (Cervarix) demonstrated that even 
seven years after vaccination, the efficacy of a single-dose immunization was non-inferior to 
that of the two- and three dose regimen [125]. This was true for HPV-16 and -18 and also for 
some non-vaccine types (HPV-31/-33/-45). During the extended time of follow-up, serum 
antibody levels to HPV-16 and -18 were only 3.7- and 2.6-fold lower in vaccine recipients of a 
single HPV vaccine dose than in the recipients of three doses. In contrast to differences in the 
antibody levels, antibody avidity is similar across the recipients of all three types of 
immunization regimen [134,135]. These findings supported more targeted research on 
efficacy of the single-dose immunization schedules. One of these clinical trials is currently 
ongoing: a dose reduction immunobridging and safety study of two HPV vaccines in Tanzanian 
girls (DoRIS) is aiming to demonstrate non-inferiority of a single dose HPV vaccination 
schedule compared with the previously approved 2 - 3 dose regimen [136]. In this case, the 
immunobridging trial represents a post-licensure comparative effectiveness study using 
vaccine immunogenicity as measure of primary outcome, which is possible due to previously 
evaluated efficacy and immunogenicity of the full-dose HPV vaccination schedule.  
In addition to the focus on dose-reduction, a mixed vaccination schedule was evaluated in the 
randomized clinical trial setting [93]. This study aimed to exploit and combine advantages of 
each of the vaccines, such as excellent immunogenicity of the bivalent vaccine and a large 
number of HPV types targeted by the nonvalent HPV vaccine. The mixed vaccination schedule, 
such as immunization of the same person with two different HPV vaccines, yielded high anti-
HPV antibody responses and demonstrated acceptable safety profile [93]. Flexibility with 
choosing the type of HPV vaccine for an organized vaccination program would increase 
market competition in vaccine price and could minimize the prognosed shortage of the HPV 
vaccines due to the expected widespread launch of vaccination campaigns [137], which are 
coordinated by the WHO for eliminating cervical cancers worldwide [138]. 
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1.2.3 HPV serology assays for detection of anti-HPV antibodies to viral capsid proteins 
In the vast majority of cases HPV infection is cleared within approximately a year. 
Consequently, studies relying on the detection of cervical HPV DNA often have bias towards 
underestimation of the total exposure to the pathogen. This was emphasized in the design of 
HPV vaccination programs when the overall exposure to the virus needs to be estimated in a 
given population [139]. Compared to the transient HPV infections, anti-HPV antibodies 
constitute a more stable marker [54]. However, not all of the papillomavirus infections result 
in a detectable seroconversion [52,54] also explaining why HPV serological assays are used 
mainly in research but not as a diagnostic tool for cervical cancer screening or triaging [140].  
HPV serology assays used in HPV vaccine clinical trials differ in their ability to detect identical 
subsets of binding and neutralizing antibodies (Fig. 6) [141]. Development of multiplexed 
formats of these serology methods was prompted by emergence of HPV vaccines with 
multiple genotypes in their formulations [142–146]. Each of these assays has its unique 
characteristics and advantages/disadvantages, described below and summarized in Table 1 
[147]. 
 
Figure 6. Schematic pattern of the detectable by the serology methods overlapping subsets of binding and 
neutralizing anti-HPV antibodies against viral capsid proteins. Red designates the total entity of VLP antibodies; 
orange circle marks subset of antibodies that are detectable by ELISA; grey – by the in vitro neutralizing assay; 
light grey – by cLIA. cLIA, Competitive Luminex immunoassay; ELISA, Enzyme-linked immunosorbent assay; VLP 
antibodies, Virus-like particle-specific antibodies [141]. Adapted from Schiller JT, Castellsague X, Garland SM. A 
review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine. 2012; 30 Suppl 5:F123-38, 
reproduced with permission from Elsevier, RightsLink Copyright Clearance Center. 
Based on the hypothesis that neutralizing anti-HPV antibodies play a key role in protection 
from HPV infection, the classical method for studying HPV vaccine immunogenicity is the HPV 
neutralization assay (NA) [97,99,123]. It measures a total subset of neutralizing 
immunoglobulins (IgM, IgG, IgA). Sensitivity of HPV neutralization assay is similar to that of an 
enzyme-linked immunosorbent assay (ELISA) but specificity is higher [97]. 
HPV ELISA is another gold standard used for measuring type-specific antibodies to HPV [148]. 
It is less laborious than neutralization assays but detects only a certain class of 
immunoglobulins depending on the class of secondary antibody used [147]. 
Competitive immunoassay (cLIA) is highly concordant to the neutralization assay [149]. The 
coefficient of correlation between cLIA and the neutralization assay reaches 0.93 for HPV-16 
and 0.95 for HPV-18 [149]. cLIA is also available in a multiplexed format [142].  
 
 21 





1. Measures function closest to 
presumed mechanism of 
protection through selective 
detection of neutralizing 
antibodies 
2. All immunoglobulin classes are 
detected 
3. Similar analytic sensitivity 
compared to a standard VLP ELISA 
4. Higher specificity compared to a 
standard VLP ELISA 
1. Requires pseudovirions for each HPV 
type 
2. Requires cell culture and time for cell 
growth 
3. Time consuming, partial automation is 
possible [99] 
4. Multiplexing requires several types of 
reporter dyes 




1. Faster than the NA 
2. Commonly used assay format 
3. Multiplexing possible (bead 
array or multispot wells) 
1. Type of secondary antibodies 
determines a single class of antibodies to 
be detected (IgG or IgA) 
2. Binding antibodies are not be 
distinguished from the neutralizing 
Competitive 
immunoassay 
1. Detects neutralizing antibodies 
2. Easily multiplexed with bead 
arrays (e.g. Luminex) 
3. Rapid, high throughput 
4. All immunoglobulin classes 
detected 
1. Only a subset of total neutralizing 
antibodies detected  
2. Requires type-specific neutralizing 
monoclonal antibodies 
3. Compromise between choosing the 
dominant epitope and keeping the type-




developed by Helena 
Faust 
1. Fast, high throughput 
2. Multiplexed, panel extension 
possible 
3. Scalable 
4. Moderately labour intensive 
when compared to NA and ELISA 
1. Type of secondary antibodies 
determines a single class of antibodies to 
be detected (IgG or IgA) 
2. Binding antibodies are not be 
distinguished from the neutralizing 
3. CV is higher than in HPV VLP ELISA 
Table 1. Serology assay types for monitoring HPV vaccine immunogenicity (adapted from [147] and expanded). 
The method used in this work for type-specific anti-HPV antibody detection is a multiplexed 
variant of HPV ELISA, called heparin-pseudovirion Luminex assay [144]. The assay employs 
pseudovirions of HPV as antigens [70,144]. Aside of being multiplexed, this assay has the 
advantage of binding of the antigen to the Luminex beads via intermediate layer of heparin, 
which ensures that only in properly folded capsids are attached [150]. 
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1.2.4 Evaluation of HPV vaccine effectiveness 
Estimations of vaccine effectiveness are usually carried out in the post-licensure settings, 
frequently referred to as “field” settings because study conditions are less controlled than 
within the clinical trials [151]. In its classical definition, vaccine effectiveness determines 
reduction in risk of disease among the vaccine recipients relative to unvaccinated. A range of 
diseases which are caused by the vaccine-targeted pathogen are generally reflected in the 
spectrum of endpoints for estimating vaccine effectiveness. In case of HPV, it extends also to 
other measurable responses which serve as proxies for disease protection.  
The range of outcomes for evaluation of HPV vaccine effectiveness can be grouped into the 
disease, virological and immunological endpoints [152]. The use of immunological endpoints 
as primary outcome measure is so far more suitable for the immunobridging studies, although 
when applied as a secondary endpoint it is a valuable measure also in the other types of study 
designs [91,92,101,110,136,153–156]. Relevance of immunogenicity measurements is of 
limited value as long as a protective antibody threshold is not determined. A second type of 
endpoints used for estimation of vaccine effectiveness are incident and persistent HPV 
infections [81,86,89,157]. The last and the most relevant outcomes, the clinical endpoints, 
reflect course of disease progression from CIN to cervical cancer [82,158–160] and are least 
immediate to occur. Within the clinical endpoints, however, quadri- and nonavalent vaccines 
have an advantage since they prevent genital warts and this can be measured shortly after 
introduction of HPV vaccination. The latter is extremely convenient in evaluation of 
population level vaccine effectiveness [161–163].  
Data on each of the endpoints can be collected in either way – actively through sampling or 
passively via register-based follow-up in case available infrastructure exists, or through their 
combination (for instance, retrieval of the biobanked samples). Vaccine effectiveness is 
measurable both in cohort and case control study design types in their different variants 
[80,82,90,157,158,164,165].  
1.3 MEANS OF CERVICAL CANCER PREVENTION IN SWEDEN 
The most effective but somehow unrealistic mean for cervical cancer prevention would be 
abstinence from sexual intercourses. Luckily, in the era of effective HPV vaccines and cervical 
screening, this appears to be unnecessary. There are numerous modifications of HPV 
vaccination and cervical screening programs worldwide. In this thesis, I will focus on Swedish 
experience. 
1.3.1 HPV vaccination 
In Sweden, the first HPV vaccine was licensed in 2006 and HPV vaccination became 
recommended by the Swedish Public Health Agency (Folkhälsomyndigheten, 2007). Initially, 
the vaccination coverage remained relatively low, barely reaching 33 % and only in a small 
number of birth cohorts [166]. Coverage of about 80 % was achieved when an organized 
school-based vaccination program was launched in 2012 [166,167]. Within this program, 10-
12 years old girls were vaccinated with three doses of a quadrivalent HPV vaccine. In addition, 
a catch-up campaign covering girls up to 18 years of age was launched in 2013, and later to 
young women up to 26 years of age. 
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Meanwhile, non-inferiority of a two-dose to the previously conventional tree dose 
vaccination schedule was demonstrated and in 2014 a reduced-dose vaccination regimen was 
approved by EMA [128]. In 2015, the Swedish national vaccination program was modified to 
a two-dose girls-only vaccination [168]. In 2019, vaccination was changed to the nonavalent 
HPV vaccine, and boys were included in August 2020 [167]. 
The Public Health Agency in Sweden is responsible for the planning and monitoring of the 
national HPV-vaccination program. There are several ways from monitoring program 
effectiveness, such as registration of all vaccinations, monitoring and investigation of the 
infection-related diseases (for instance, by using data collected by The Swedish National 
Cervical Screening Registry), seroepidemiological surveillance and monitoring of the 
epidemiology of virus types. 
From 2013 on, individual-level records of all vaccinations within the Swedish vaccination 
programs are collected by The Swedish National Vaccination Register (NVR) under the Public 
Health Agency of Sweden [169]. It contains the following data: vaccination date, personal 
identifying number (PIN) of the vaccine recipient, type of vaccine being administered, vaccine 
batch number and the healthcare provider who performs immunization. The place of 
registration of the vaccine recipient is uploaded from the population register. In addition, 
person-wise data on HPV vaccinations which might be not covered by the organized 
immunization program, is collected by The Swedish Prescribed Drug Register (PDR), National 
Board of Health and Welfare [170]. The PDR was established in 2005 to increase patient safety 
and it collects data on each dispensation at a pharmacy. PDR data is used by researchers, 
authorities, analysts etc. and contains information about the patient (sex, age, residence), 
product (drug code, drug name, strength, inclusion in the pharmaceutical benefits scheme), 
prescription (quantity/number of packages, strength, date of prescription, date of purchase), 
costs (total cost, patient cost, region’s cost and additional patient cost) and the prescriber.  
1.3.2 Cervical screening 
Organized cervical cancer screening started in Sweden at the end of the 1960 [171]. It was 
based on detection of cellular changes and over the following decades reduced notably 
cervical cancer incidence and mortality (Fig. 7). Within this program, women resident in 
Sweden were invited for cervical sampling either at a three- (23 - 50 years old) or five-year 
interval (50 - 60 year old) [171]. 
Within the organized cervical cancer screening program, women resident in Sweden receive 
invitation letter for attending cervical sampling during the year they turn 23. Participation in 
the organized screening is free of charge. Today, the program has more elaborated algorithm 
that utilizes both cytology and HPV-typing as primary screening methods depending on age 
of the screening participant [171]: 
- 23 - 30 years-old women are screened using a liquid cytolgy method at a three-year 
interval; 
- 30 - 49 years-old women are tested for cervical pathology using an HPV DNA detection 
method (HPV test) also at a three-year interval, with additional cytological test when 
turning 41; 
- 50 - 64 years-old women are screened also with HPV test but only each seventh year; 
- women who did not attent sceening at 64 continue receiving annual invitations until 




Figure 7. Time trends for age-standardized rates of cervical cancer incidence and mortality in Sweden, all age 
groups. Curve of the incidence rates has red color and of mortality - green. Visualized with NORDCAN (Nordic 
tool for cancer information, planning, quality control and research) [173].  
Individual-level data about the cervical screening is collected by The Swedish National 
Cervical Screening Registry (NKCx) for monitoring quality and performance of the preventive 
program [174]. It has a 100 % national coverage and includes all data on issued invitations for 
cervical screening, on results of cytological and histopathological evaluations. Fine structure 
of collected data and its completeness make NKCx a valuable source of information for the 




The overarching aim of this thesis was to estimate effectiveness of HPV vaccination by 
characterizing duration, breadth and magnitude of vaccine-induced anti-HPV antibody 
responses and by investigating the reasons for cervical lesion development among the 
recipients of HPV vaccines. In addition, we aimed to better understand biological 
characteristics of HPV infection, which prompted us to study dynamics of infection-induced 
humoral responses to HPV and their relation to sexual activity, positivity to HPV DNA and 
clinical manifestations. These aims are summarized in Table 2. 
Paper Short name Study aims 
I. Concordance between HPV DNA 
and anti-HPV antibodies 
To characterize anti-HPV antibody response dynamics 
to a subset of anogenital HPV types and to evaluate 
their correlation with the cumulative presence of HPV 
DNA of the same type in the longitudinally collected 
serial samples. 
II. Infections with multiple HPV types To assess whether seropositivity to multiple 
anogenital HPV types is associated with current 
multiple anogenital HPV infections, abnormal 
cytology, or seropositivity for cutaneous HPVs. 
III. Long-term immunogenicity of 
vaccine-targeted types - a head-to-
head vaccine comparison 
To compare Gardasil- and Cervarix-induced anti-HPV 
16 and 18 antibody levels head-to-head up to 12 years 
post vaccination. 
IV. Long-term immunogenicity of 
cross-reactive responses - a head-
to-head vaccine comparison 
To compare Gardasil- and Cervarix-induced 
seropositivity, antibody levels and antibody avidity for 
non-vaccine HPV types up to 12 years 
postvaccination. 
V. Cervical lesions among the HPV 
vaccinated young women 
To investigate whether development of cervical 
intraepithelial lesions in HPV-vaccinated young 
women associated with vaccine-targeted HPV types 
or not. 
Table 2. Summary of study aims targeted in each of the papers within the scope of this thesis. 
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4 MATERIALS AND METHODS 
4.1 STUDY DESIGNS 
Papers I and II are based on the same research project and are both longitudinal cohort 
studies with repeated measurements at two time points (Fig. 8). This enabled us to estimate 
seroconversion rates over the follow-up time, to establish the association between HPV DNA 
positivity and type-specific anti-HPV antibody levels, to study the effect of infections with 
multiple HPV types, etc. Measurement from two time points also allowed to estimate 
protective effect of anti-HPV 16 antibodies induced by HPV infection (not covered by this 
thesis) [58]. Cohort types of study designs are rated high by the level of epidemiological 
evidence they can provide. There are, however, certain disadvantages: cohort studies are 
usually costly and time consuming. In contrast to case-control studies and clinical trial designs, 
cohort studies may be more subject to bias and are not always appropriate for studying rare 
events.  
 
Figure 8. Schematic description of the study design in papers I-II (figure created from [54,178]). 
Cervical cancer screening settings appeared to be extremely useful in collecting different 
types of biological material and study subject information that allowed achieving multiple 
aims of this study. Repeated measurements of HPV DNA within the same study subject was 
also helpful in overcoming the documented problem of low sensitivity of HPV serology assays, 
known to arise from the transient nature of HPV infections. 
Papers III and IV arise from one data source and have an identical longitudinal cohort study 
design, which can also arguably be classified as repeated measurement cross-sectional study. 
The cohorts were established by the long-term register-based follow-up of women who were 
earlier enrolled into the one of the phase III clinical trials of HPV vaccines, either Cervarix or 




Figure 9. Schematic description of the study design in papers III-IV (figure created from [126]). FMC: Finnish 
Maternity Cohort. 
Paper V has a case-control design, nested among the vaccinated women who attended 
cervical cancer screening program in Sweden (Fig. 10). We excluded women with abnormal 
cytology/biopsy results before vaccination, abnormal cytology/HPV test that were not 
confirmed by histology, females with lesions of vagina and women with other types of 
histological pathologies of cervix. To increase the likelihood of being HPV-naïve by the time of 
vaccination, we limited the cohort to females immunized at a relatively young age (< 17 
years). Sampling location was narrowed to the greater Stockholm area, which represents 23% 
of the total Swedish population and has high coverage of cervical cancer screening program. 
The proportion of cervical abnormalities that are routinely detected in cervical screening in 
the greater Stockholm area is similar to that which is reported by other regions of Sweden. 
Among the resulting subset of women, rare cases with cervical lesions despite HPV 
vaccination were matched to the disease-free controls at a 1:2 ratio. Samples from this 
matched cohort were then retrieved from the cervical cytology biobank for HPV DNA typing. 
 
Figure 10. Schematic description of the study design in paper V (figure created from [164]). 
Although on the hierarchy of epidemiological evidence this type of study design is less 
valuable than clinical trials and cohort study designs, case-control studies are in practice 
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easier to implement when more rare events, such as cervical lesions among young HPV-
vaccinated women, shall be analyzed. Further, they are more convenient in studying multiple 
exposures and are usually less costly than the cohort studies [179]. 
4.2 STUDY POPULATIONS 
In papers I and II, the study population comprised of 2,037 women of 20 - 64 years, who 
attended cervical cancer screening program in Slovenia and consented for cervical sampling 
and for blood withdrawal for the anti-HPV antibody testing. These women were also asked to 
complete the questionnaires about their HPV vaccination status and about a subset of co-
factors which are recognized to play role in cervical lesion development. Biological specimens 
and questionnaires were collected during two consecutive rounds of the study three years 
apart. Women, who claimed to have been vaccinated with any of the HPV vaccines (N=13), 
were excluded.  
For our research purposes, the data on HPV DNA and anti-HPV antibody status from the two 
timepoints, as well as cytology results from the second screening round were available for 
1,848 women.  
In papers III and IV, the study population comprised young women (average age at sampling 
27 years), who were vaccinated with three doses of one of the HPV vaccines 7 - 12 years prior 
to sampling (Table 3). At sampling, the women were pregnant and were residing in Finland.  
 
Bivalent HPV vaccine 
(Cervarix, N=730) 
Quadrivalent HPV vaccine 
(Gardasil, N=337) 
Age at vaccination (mean (SD)) 17.01 (0.48) 17.07 (0.63) 
Age at sampling (mean (SD)) 26.50 (1.34) 27.29 (1.62) 
Interval from vaccination, years N (%) 
7 63 (8.6) 19 (5.6) 
8 114 (15.6) 37 (11.0) 
9 149 (20.4) 43 (12.8) 
10 208 (28.5) 73 (21.7) 
11 185 (25.3) 86 (25.5) 
12 11 (1.5) 79 (23.4) 
Pregnancy sample serial number N (%) 
1 353 (48.4) 163 (48.4) 
2 280 (38.4) 133 (39.5) 
3 79 (10.8) 37 (11.0) 
4 15 (2.1) 4 (1.2) 
>4 3 (0.4) 0 (0.0) 
Table 3. Characteristics of study cohorts in the HPV vaccine comparison study (papers III and IV). 
At the age of 16 - 17 years, these females were enrolled in one of the clinical trials of HPV 
vaccines, the bivalent Cervarix (clinical trial PATRICIA) and the quadrivalent Gardasil (clinical 
trial FUTURE II). The girls consented to a passive follow-up through the Finnish healthcare-
related registries and to a subsequent linkage of their personal identifiers with the data in the 
Finnish Maternity Cohort (FMC) biobank. This allowed the prospective retrieval of serum 
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samples and a head-to-head comparison of long-term immunogenicity between the two 
vaccines in the independent settings. 
The age-matched cohort of Swedish women who were not vaccinated with any of the HPV 
vaccines, was used a reference group. Serum samples from these women were obtained from 
the Region Skåne biobank. Estimates of naturally acquired anti-HPV antibody responses 
within the nonvaccinated cohort allowed us to compare HPV vaccine-induced cross-reactivity 
with the HPV seroprevalence resulting from seroconversion to HPV types that circulate in the 
population.  
In paper V, the study population comprised a cohort of young women having been HPV-
vaccinated at <17 years of age and attended cervical cancer screening program in Sweden. 
Selection of eligible cases and a cohort of controls was followed by case-control matching, 
sample retrieval and HPV DNA typing. 367 women entered the final case-control cohort 
analysis (Table 4). All females were vaccinated with at least one dose of HPV vaccine on 
average at 16 years of age. Of these, 88 % of cases and 91.3 % of controls received three doses 
of HPV vaccine. Women who developed cervical neoplasia were on average 23 years old at 
the time of diagnosis, which corresponds to their first screening round in an organized cervical 
cancer screening program. 
 
CIN 1-3 
controls (N=242) cases (N=125) 
Vaccine type, n (%) 
quadrivalent 240 (99.2 %) 125 (100.0 %) 
quadrivalent and 
bivalent 
2 (0.8 %) 0 (0 %) 
Number of doses, n (%) 
1 6 (2.5 %) 6 (4.8 %) 
2 15 (6.2 %) 9 (7.2 %) 
3 221 (91.3 %) 110 (88.0 %) 
Age at vaccination, years Mean ± SD 15.79 ± 0.82 15.91 ± 0.78 
Age at sampling, years Mean ± SD 22.68 ± 1.64 22.92 ± 1.68 
Interval between vaccination and 
sampling, years 
Mean ± SD 6.89 ± 1.44 7.00 ± 1.51 
Age at diagnosis, years Mean ± SD - 23.00 ± 1.70 
Table 4. Summary characteristics of the HPV-vaccinated case-control cohort which developed CIN1-3 or was 
free from disease (paper V, adapted from [164]). Reproduced with permission from the John 
Wiley and Sons, RightsLink Copyright Clearance Center. 
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4.3 DATA SOURCES 
Data collection included both “dry” (register-based) and “wet” (experimental) parts. The 
second part consisted of test results of sample analyses around the time of their collection 
(no storage in a biobank) or after retrieval from the biobanks.  
In the Slovenian cervical screening cohort study (papers I-II) we used a dataset, which was 
collected prospectively over the study rounds and contained pseudonymized identifiers, test 
results of the biospecimen (HPV DNA status, anti-HPV antibody status, cervical cytology 
result) and responses from the self-reported questionnaires (age, parity, HPV vaccination 
status, smoking status, number of lifetime partners, number of new male sex partners 
acquired during the last three years and within the last year). Cervical swabs were used for 
HPV DNA-testing and for assessment of cytological status (Institute of Microbiology and 
Immunology, Faculty of Medicine, University of Ljubljana, Slovenia). The algorithm of HPV 
DNA typing by the Abbott RealTime High Risk HPV assay, Hybrid Capture 2 HPV DNA assay, 
Linear Array HPV Genotyping Test, INNO-LiPA HPV Genotyping Extra Test, and an in-house 
GP5+/GP6+ PCR is described elsewhere [178]. Serum type-specific anti-HPV antibodies were 
detected at the Karolinska Institute using the heparin-pseudovirion serology assay 
(Department of Laboratory Medicine, Karolinska Institutet, Sweden) [54,70,144].  
In papers III-IV, register-based linkages were followed by the laboratory analyses. Records on 
the HPV vaccine clinical trials participants (PATRICIA and FUTURE II) that are stored at the 
Register of Vaccinated Individuals (RVI) were linked to the FMC biobank using the PIN of the 
former clinical trial participant. This allowed identification of the available biobanked serum 
samples from the HPV-vaccinated women. Aliquots of these samples were retrieved from the 
FMC biobank and tested for presence of anti-HPV antibodies using heparin-pseudovirion 
Luminex assay (Karolinska Institutet). The final dataset that was generated by this study and 
consisted of the following variables: pseudonymized personal identifier, information from the 
RVI (type of vaccine, age at first dose of HPV vaccine, vaccination date for each of the received 
dose), FMC biobank data (pseudonymized sample code, sampling date, serial number of 
sample/pregnancy) and results of the laboratory analysis (HPV seropositivity status, anti-HPV 
antibody levels and avidity).  
In paper V, in a similar way, data from NVR were linked to the NKCx database by the PIN 
numbers. This allowed the identification of women who attended cervical screening after 
having been immunized with any of HPV vaccines. Data on the individual’s personal number, 
vaccine type, vaccination dates and vaccine dose number were extracted from the NVR and 
selected PIN were linked to the NKCx. Variables that were used from the NKCx register are: 
person identifier, age by 2018, sample location county, SNOMED codes for cytology diagnosis, 
age at diagnosis, date of cytology sample is taken, identification of cytology sample, number 
of cytology screenings, ID of histopathology diagnosis, date for histopathology sampling etc. 
The selection of eligible case-control cohort and status verification among the cases was 
performed using the subset of SNOMED codes for cervical diseases [180]. The stratification of 
cases by their CIN grade was based on the uniformed disease classification system. Cervical 
samples from 125 cases (vaccinated women with CIN1 - 3) and 242 controls were retrieved 
from the cytology biobank of the Karolinska University Laboratory and analyzed for presence 
of type-specific HPV DNA. The final dataset, which was used for analysis, contained data on 
pseudonymized patient ID, sample ID, case-control status, ordinal number for the case-
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control strata, grade of cervical neoplasia, type of vaccine, number of doses, vaccination date 
for each vaccine dose, sampling date, diagnosis date, internal quality control (β-globin copy 
number), and test results for 37 genital HPV types (HPV DNA positive/negative). 
Biobanks 
The Finnish Maternity Cohort (FMC) biobank (papers III-IV)  
The FMC biobank was established in 1983 for cryopreservation of residual volumes of sera 
from samples obtained within the congenital disease screening program (first trimester of 
pregnancy) [181]. Since that time, practically all women having had their pregnancy in Finland 
have contributed to the biobank collection. FMC register allows for the linkages with the 
Finnish population-based health registers [182]. 
The cytology biobank of the Karolinska University Laboratory / National Clinical Cytology 
Biobank (paper V) 
This clinical cytology biobank was established in 2011 as extension of the organized cervical 
cancer screening program [183]. Today, it collects cytology cell swabs from virtually all 
gynecological samplings taken within the Stockholm County (about 700,000 samples). The 
biobank stores cervical cell fractions (600 µl) of liquid-based samples at -25°C for preventing 
DNA, RNA and proteins degradation, and for maintaining cell morphology. Quality controls of 
the stored material are performed twice a year. 
4.4 LABORATORY METHODS 
4.4.1 Multiplex HPV serology assay: heparin-pseudovirion Luminex assay 
This technique is based on an antigen-antibody binding similar to classical ELISAs but 
transformed into a high-throughput method through multiplexing [184]. The assay measures 
antibodies to multiple HPV types at the same time, which in turn facilitates evaluation of HPV 
type-specific antibody responses in a large numbers of serum samples. This is achieved with 
the use of Luminex suspension array technology (xMap): multiple light sources inside the 
Luminex analyzer excite the internal bead dyes that identify each microsphere particle and 
any fluorescent reporter molecules captured during the assay (Fig. 11, B) [185]. The 
instrument records dozens of readings for each bead set and produces a distinct result for 
each analyte in the sample. Using this process, xMAP allows multiplexing of up to 500 unique 
bioassays within a single well [185]. In the HPV serology multiplex method, beads with 
different emission profile carry pseudovirions of a specific HPV type (Fig. 11, B).  
Validation of the method demonstrated a strong type-specific correlation with HPV infection 
as measured by the cervical HPV DNA positivity [144] was shown to be suitable for studying 
antibody responses after/during HPV infection and after HPV vaccination [184]. In the 
heparin-pseudovirion Luminex assay, mammalian cell-derived pseudovirions are used as 
antigens. The pseudovirions contain both L1 and L2 capsid proteins, which mimic virions but 




Fig. 11. Heparin-pseudovirion Luminex assay principle [184]. A. Schematic overview of the method. B. Luminex 
assay principle. On panel A: polystyrene Luminex beads coated with heparin are depicted with gray color; 
human papillomavirus pseudovirions are marked with orange spherical structures with bound antibodies; 
human antibodies are depicted with blue color, mouse anti-human – with green and phycoerythrin-tagged 
goat anti-mouse antibodies are designated with red. On panel B: polystyrene Luminex beads are depicted as 
gray spheres; two lines of red and light green color represent lasers of Luminex analyzer. 
During preparation steps, polystyrene Luminex beads are coated with heparin (gray color on 
Fig. 11, A), which selectively binds properly folded pseudovirions (orange spherical structures 
on Fig. 11, A) [150]. During the sample analysis, pseudovirion-heparin coated beads are 
incubated with human sera, allowing binding of the anti-HPV antibodies. Wells of the filter 
plates are washed and the remaining complexes are incubated for one hour with anti-human 
mouse antibodies. Following washing, phycoerythrin-tagged goat anti-mouse antibodies are 
added incubated for 30 minutes, which precedes detection of the bound complexes (Fig. 11, 
B). Today, VLPs of at least 23 HPV types, two human polyomavirus types and antigen of HSV2 
(gG2 protein) were validated using this method [70,186–188].  
The quality of the assay is monitored in an HPV type-specific manner using the negative (sera 
from children) and positive control panels. The latter consists of monospecific sera and sera 
from subjects who are seropositive to multiple HPV types. The cut-off for seropositivity is 
defined by the reactivity of a negative control panel of sera from children six month to twelve 
years of age (N=±200). Cutoff values of each type of HPV is assigned according to 
recommendations of the WHO HPV Laboratory Manual (average of MFI values (MFI, median 
fluorescence intensity) of a negative control serum panel +3 standard deviations) [148]. For 
HPV-16 and -18, antibody levels are translated into the international units (IU) by calibrating 
MFI values of the test sample against the reference International Standard (IS) sera 
established by the WHO. The IS standard sera are provided by the National Institute for 
Biologicals Standards and Control (NIBSC) [148,189,190].  
There are three modes of calibration that can be used for conversion of MFI values into the 
IU: PLL (parallel line model), wPLL (weighted parallel line model) and RFL (reference line 
model) [191]. Although the WHO HPV laboratory manual recommends use of the PLL method, 
higher reproducibility was demonstrated using the RFL model [192]. According to our 
experience, the latter is indeed more suitable, particularly when using the postvaccination 
sera which often contains high titres of anti-HPV antibodies. However, for most of the HPV 
types IS are not yet established. For this reason, we used arbitrary assigned units (AU), defined 
by measurements from a pool of sera from vaccinated individuals, when investigating 
antibodies against HPV-6, -11, -31, -33, -35, -39, -45, -51, -52, -56, -58, -59, -68, and -73, 
(described in Paper IV). 
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Avidity, strength of binding between the antigen and antibody, was also measured using the 
heparin-pseudovirion Luminex assay. The HPV type-specific avidity index (AI) is estimated 
after antibody-binding following a 10 minute-incubation in 2.5 M ammonium thiocyanate 
[193]. The AI is defined as a percentage of MFI values in the well which was treated with 
NH4SCN compared to identical dilution treated with the PBS only.  
4.4.2 High-throughput HPV DNA detection and typing 
Initially developed at the German Cancer Research Center [194], the method of multiplexed 
HPV DNA typing is nowadays used also with the modified general primers (MGP) described 
elsewhere [194,195].  
Multiplexed HPV genotyping is based on PCR products from MGP (or GP5+/6+) PCR, where 
MGP the reverse primers are biotinylated, and on HPV type-specific probes which are coupled 
to the polystyrene beads through an amino group (Fig. 12) [194,195]. Polystyrene Luminex 
bead are classified by the color of their inner dye, so that the HPV-type specificity is labeled 
and is detectable even after mixing the probe-bead solutions for different HPV types. The 
biotinylated PCR products are then allowed to hybridize to the bead-bound probe. At the next 
step, streptavidin-R-phycoerythrin binds to the bead-bound biotinylated PCR product, which 
is then detected by the laser in the Luminex machine. A red laser classifies the beads that are 
identified by their distinct orange/red emission profile and a green laser detects 
phycoerythrin bound to the hybridized complexes [196], which allows quantification of the 
captured PCR product. We used type-specific probes for HPV-6, -11, -16, -18, -18v (a letter 
that follows the HPV type stands for virus variant), -26, -30, -31, -33, -35, -35v, -39, -40, -42, -
43, -45, -51, -51v, -52, -53, -54, -56, -58, -58v, -59, -61, -66, -67, -68a, -68b, -70, -73, -74, -81, -
82, -83,- 86, -87, -89, -90 and -91 [164]. The method allows simultaneous detection of at least 
twice as many HPV types as we used [194]. 
 
Fig. 12. Schematic overview of multiplex HPV genotyping of GP5+/6+-PCR products using bead-based assay. 
ORF, open reading frame [194]. Reproduced from Markus Schmitt et al. Bead-Based Multiplex Genotyping of 
Human Papillomaviruses. J of Clin Microbiol, Feb 2006, 44 (2) 504-512; DOI: 10.1128/JCM.44.2.504-512.2006, 
with permission from ASM, RightsLink Copyright Clearance Center. 
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4.5 STATISTICAL METHODS 
Variables, estimates, statistical methods and analysis tools used within the research projects 
of this thesis are summarized in Table 5. In papers I and II, we evaluated reproducibility of the 
serological assay on each of the study rounds by estimating agreement between categorical 
data (κ statistics) and between numerical (R2). Less known than R2, which measures strength 
of linear association between the variables, κ statistics is based on comparison of the 
observed proportion of agreement between the two readings, made on two different 
occasions, with the proportion of agreements that would be expected by chance [197]. In our 
studies, estimation of sensitivity and specificity of the serological assay relied on the HPV DNA 
status as gold standard. Due to known transient nature of HPV infections, we estimated 
serology assay performance with cumulative HPV DNA status from both timepoints. 
Seroconversion was defined as seropositivity at follow-up among women who had been 
seronegative at baseline. Strength of association between the HPV DNA/cytology/number of 
partners etc and anti-HPV antibody statuses were measured by odds ratios (OR), meaning 
ratio of the odds for becoming antibody positive when, for instance, one is HPV DNA positive 
compared to the anti-HPV DNA negative. 
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Table 5. A summary of statistical methods used in each of the papers within the scope of this thesis. 
In papers III and IV, each vaccine recipient group within two-year intervals from vaccination 
was stratified by the quartiles of their anti-HPV16 antibody levels. This allowed for a more 
detailed evaluation of seropositivity, anti-HPV antibody levels and avidity of the genital HPV 
types. Proportions of seropositivity were estimated with Wald confidence intervals. 
Comparison of seropositivity proportions were carried out with the Fisher exact test (two 
group comparisons, for instance, vaccine recipient groups) and χ2 test for trend in proportions 
(more than two comparison groups, for instance, anti-HPV16 antibody quartile groups). 
Comparison of median anti-HPV antibody responses and avidity across the groups was as well 
performed with the non-parametric tests. Wilcoxon rank-sum test was used for testing 
differences in means across two groups and Kruskal-Wallis – across three or more groups. 
This was justified by the non-normal distribution of the data and, in some more detailed 
analyses, by the limited sample sizes. 
Differences in means of antibody levels and avidity across the anti-HPV16 antibody quartiles 
were quantified with linear regression (differences between the log-transformed type-
specific anti-HPV antibody levels in each of the anti-HPV antibody quartile group), where the 
lowest anti HPV-16 quartile group was used as a reference group.  
In paper V, logistic regression was used to estimate association between the HPV DNA 
positivity and the clinical outcome (CIN 1-3) in a case-control study. To control the potential 
confounding by the number of HPV vaccine doses, we further adjusted our statistical model 
for the corresponding variable. The other factors which could otherwise influence the 
association between the exposure and the outcome were initially ruled out in our study 
design by limiting age at vaccination to 17 years and by matching the cases with the controls 
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(case-control sets were matched by the age at vaccination, type of HPV vaccine and date of 
cervical sampling). Estimates for non-vaccine HPV types with less than five events of HPV DNA 
positivity were not considered for further analysis. HPV types with no positive HPV DNA 
events in the control groups were evaluated using the StatCalc module of EpiInfo (version 
7.2.0.1) because its default algorithm adds 0.5 to each sum of HPV DNA positive and negative 
women in both case and control groups.   
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5 ETHICAL CONSIDERATIONS 
In the projects in this thesis, we conducted register-based research, laboratory analyses 
(testing of human blood serum and cervical samples), statistical analyses and prepared the 
manuscripts, which was all done at Karolinska Institutet. Corresponding research plans were 
reviewed and approved by the institutional ethical review boards of the local and 
collaborative parties (Table 6). Biological material was obtained from different types of 
sources and populations. Samples that were used in the studies, were taken either from 
participants of a cervical cancer screening program or from participants of screening for 
congenital infections during their first trimester of pregnancy. Informed consent was obtained 
from study participants prior to sampling. In the research project described in papers I - II, 
most of the study participants have filled in questionnaires, thus provided additional sensitive 
information. Key files are handled by the collaborators or securely stored by the local 
database administrator. Identities of the study participants and their interests are protected 
by law. Deanonymization of the identifiers is not possible. Pseudonymized identifiers can be 
traced to the individual only by the authorized personnel and in accordance to the aims stated 
in the ethical approval of a study. 
Paper Short name Ethical approvals 
I - II. I. Concordance between 
HPV DNA and anti-HPV 
antibodies.  
II. Infections with multiple 
HPV types. 
Each round of the study was conducted in accordance with the ethical 
standards of the Helsinki Declaration and was approved by the 
National Medical Ethics Committee at the Ministry of Health of the 
Republic of Slovenia (consent numbers for the baseline and second 
screening rounds of the study: 83/11/09 and 109/08/12, respectively). 
Written informed consent was obtained from all study participants.  
Antibody testing at Karolinska Institutet for detecting anti-HPV 
antibodies was performed according to permission from the ethical 
review board (diary number 2016/919-31/2). 
III - IV. III. Long-term 
immunogenicity of 





reactive responses - a 
head-to-head vaccine 
comparison. 
The FUTURE II and PATRICIA trials, establishment of registers for HPV 
vaccinated individuals and their register-based follow-up: approved by 
the Finnish National Ethical Review Board (ETENE/Tukija) (Dnr’s: 
52/04/02 and 17/04/04). The FMC-samples were collected, based on 
informed consent, and maintained for scientific research by Finnish 
law (number 327/2001:1). Linkage of the intervention registers, the 
FMC, the FCR and other health registers was approved by the Finnish 
National Institute for Health & Welfare (THL/1289/5.05.00/2010).  
Antibody testing at Karolinska Institutet for detecting anti-HPV 
antibodies and for conducting serological survey of Swedish reference 
population: approved by the Ethical review board (Dnr 2016/919-
31/2).  
Antibody testing of Slovenian reference population: ethical 
considerations mentioned in Paper I and II. 
V. V. Cervical lesions among 
the HPV vaccinated young 
women. 
Study approved by the Stockholm Regional Ethical Review Board 
(Dnr. 2016/919-31/2). Informed consent from the study participants 
was not required. 
Table 6. Ethical approvals for each of the papers within the scope of this thesis. 
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In papers I-V, from the preanalytical stages of sample collection or retrieval from the 
biobanks, and through the following steps of laboratory testing, statistical analysis and 
manuscript preparation, individual numbers of all study participants were pseudonymized. 
In paper V, Swedish women who were vaccinated with any of the HPV vaccines and developed 
a CIN of any grade were followed up through the registers and were matched with the 
disease-free vaccinated controls. The ethical review board decided that signed informed 
consent was not needed from the study participants because of the pseudonymization of 
personal identifiers and due to the use of archival samples. Register-based research work was 
conducted with the pseudonymized identifiers. Cervical samples from this case-control 
cohort were retrieved from the cytology biobank and typed for HPV DNA, with yet another 
pseudonymization prior to laboratory testing. Disease status was masked from the laboratory 
personnel until the completion of laboratory analysis and was link to the pseudonymized 
identifiers prior to statistical analysis step.  
In our practical experiments, we used the E. coli safety stain XL10-Gold (Ultracompetent Cells) 
and the immortalized mammalian cell line 293 TT (derivate of human embryonic kidney cells 
HEK 293, expressing a mutated SV40 large T antigen [98]) to produce antigens for the in-house 
serology test kits [98,198]. The work was done in a BSL2 laboratory. Safety risks and 
requirements applicable to handling of human samples were assessed. 




6 MAIN FINDINGS AND DISCUSSION 
6.1 NATURALLY ACQUIRED TYPE-SPECIFIC ANTIBODIES MARK HPV INFECTION AND 
CLINICAL OUTCOME 
Determination of the serology assay performance:  
We observed that the presence of type-specific serum antibodies is strongly associated with 
the presence of cervical HPV DNA, showing an average OR of 8.1 for HPV-16, -18, -31, -33, -
35, -39, -45, -52, -56, -58, -59. Sensitivity of the serology assay was on average 51.5 % and 
specificity was 87.1 %.  
Baseline seropositivities to multiple genital HPV types are common 
At baseline, 65.3 % of women were seropositive to at least one of the 15 anogenital HPV 
types, being highest for HPV-16 (25.2 %), HPV-58 (18.7 %) and HPV-6 (18.2 %). 22.9 % of 
women were seropositive for a single HPV type only, while 42.4 % were positive for multiple 
types. The seroprevalences of the studied non-genital types HPV-3,-5,-15,-32,-38,-76 ranged 
between 4.8 % and 19.9 %. In serum samples from women seropositive to multiple anogenital 
HPVs, non-genital types were more likely to be detected than in the other groups, most 
notably for HPV-32: almost 77 % of women seropositive to HPV-32 belonged to the group of 
women with multiple anogenital HPV types. The seroprevalences across the polyomaviruses 
MCPyV and JCPyV were similar (68.8 % and 66.5 %, respectively).  
Dynamics of seropositivity to HPV: antibody stability, seroconversion and seroreversion 
Seropositivity to most of the anti-HPV antibodies had a high likelihood for persisting over the 
three years of follow-up: more than 75 %, of women who were positive to anti-HPV-56, -59, 
-58, -16 and -31 at baseline had detectable antibodies at the follow-up. Positivity to anti-HPV-
35, -39 and -45 was least stable, meaning that only 40.3 %, 49.5 % and 52.6 % of baseline 
seropositive women three years after had detectable antibodies. Seroconversion to HPV-35, 
-6 and -11 (9.7 %, 10.5 %, and 8.0 %, respectively) occurred more often than to the other 
types.  
When stratifying by the number of HPV types detected serologically within the same 
individual, most of the study participants over the follow-up time remained in the same group 
of their antibody status (antibodies to 0, 1 - 2, 3 - 15 HPV types). 75.1 % of women in the group 
with ≥ 3 HPV types remained seropositive three years later. In group positive to 1 - 2 HPV 
types, 20.5 % of women seroreverted and became seronegative. In contrast, 35.3 % of initially 
seronegative women seroconverted by the time of repeated measurement. 
Determinants of HPV seropositivity: presence of HPV DNA in the cervix and abnormal cytology 
Multiple infections (seropositivity against at least two HPV types) in cumulative serological 
estimates were detected in 53.3 % of women. Once seropositive, women on average had 
antibodies to three HPV types. 
Compared to the entire study cohort, seropositivity to three or more anogenital HPV types 
was observed among the women who were younger (median 35 years at baseline) and self-
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reported a higher number of lifetime sexual partners (median = 4). At baseline, seropositivity 
for multiple anogenital HPV types was associated with (i) presence of any HPV DNA at baseline 
(χ2 = 68.8; p < 0.0001), (ii) presence of DNA of ≥2 HPV types at baseline (χ2 = 58.6; p < 0.0001), 
(iii) presence of any HPV DNA at follow-up (χ2 = 22.9; p < 0.0001), and (iv) abnormal cytology 
(χ2 = 9.8; p = 0.0017). Baseline antibody positivity for multiple anogenital HPV types did not 
influence detection of DNA of multiple HPV types at the follow-up (χ2 = 2.9; p = 0.087). At 
follow-up, seropositivity to multiple anogenital HPV types was strongly associated with (i) 
baseline HPV DNA positivity (any HPV χ2 = 111.3; multiple HPV DNA χ2 = 72.9; all p < 0.0001), 
(ii) any HPV DNA positivity at the follow-up (χ2 = 63.9; p < 0.0001) and (iii) multiple HPV DNA 
positivity at the follow-up (χ2 = 11.4; p < 0.0008).  
Determinants of HPV seropositivity dynamics: cervical HPV DNA positivity and acquisition of 
a new sex partner 
Seroconversion to HPV-16, -31, -39, -45, -52, -56, -58 and -59 strongly associated with 
presence of cervical HPV DNA at baseline. HPV DNA positivity among the seronegative women 
strongly associated with seroconversion at follow-up, in particular for HPV-58 (OR=46.2; 95 % 
CI: 8.3-257.0) and HPV-39 (OR=24.9; 95 % CI: 7.3-84.8). Acquisition of a new sex partner 
associated with seroconversion for HPV-6, -16, -33, -35 and -56 (OR=1.8; 95 % CI: 1.3-2.6; 
OR=1.8; 95 % CI: 1.2-2.6; OR=1.9; 95 % CI: 1.2-2.9; OR=1.5; 95 % CI: 1.0-2.1; OR=2.0; 95 % CI: 
1.2-3.2, respectively).   
Compared to women with a decreasing number of HPV type-specific antibodies, 
seroconversion to 1 or more types of HPV was associated with HPV DNA positivity at baseline 
(OR= 2.0; 95 % CI 1.23-3.34; p= 0.0046), at follow-up (OR= 2.6; 95 % CI 1.43-4.65; p= 0.0013), 
or with a self-reported new sex partner (OR= 1.5; 95 % CI 1.07-2.22; p=0.0221). In this type of 
analysis other parameters did not associate with HPV antibody dynamics.  
Summary 
Collectively, we found that characteristics of type-specific anti-HPV antibodies to the most 
common oncogenic HPV types (HPV 16 and 18) apply also to the other HR HPVs. In particular, 
serum antibodies to HPV (i) associate with cervical HPV DNA positivity in a type-specific 
manner; (ii) stable over time; (iii) appear with a certain delay and, (iv) when using cervical HPV 
DNA as standard, average sensitivity of detection is around 50 %, which is similar to that of 
HPV 16. In addition, (v) serum antibodies to multiple anogenital HPV types associate with 
presence of HPV DNA and with abnormal cytology, (vi) presence of antibodies to anogenital 
HPVs associate with presence of non-genital HPVs and (vii) seropositivity to multiple HPV 
types was highly stable over time. Our results on HPV DNA in serial cervical swabs further 
showed to be valuable in validation of the serology assay as repeated sampling for exposure 
may improve sensitivity without impairing specificity. 
Discussion 
We demonstrated that the cumulative measurements improve the single point estimates. 
However, improvement in pseudovirion-Luminex assay sensitivity were to some extend 
papillomavirus species-dependent when measurements of HPV DNA positivity at both time 




The study has several unique strengths in type of design, compliance of study cohort, range 
of methods that were employed and in its overall timeliness. In addition, detection of 
serological responses to HPV infection and testing for the HPV infection were done with 
validated assays. This was important for evaluation of type-specific association between the 
anti-HPV antibodies and HPV DNA infection. Heparin-pseudovirion Luminex serology assay 
has the widest panel of the antigens yet described in the literature. 
There are also some weaknesses in our study, such as a relatively large number of women (N 
= 32) who have had their cytology results within the “gray zone” (classified as atypical 
squamous cells of undetermined significance). We have added these cases to the sub-cohort 
with abnormal results, assuming the worse direction of the outcome, although it could 
introduce some bias towards the null hypothesis (no association between seropositivity to 
multiple HPV types and cervical lesions). Another limitation is relatively limited number of 
HPV types for studying multiple infections. In addition, at follow-up we could not evaluate 
performance of HPV-68 because the different subtypes of this genotype were used in the HPV 
DNA primers used for identifying infections and in the L1 sequence of plasmid construct used 
for serology antigen production. This may have resulted in detection of anti-HPV antibodies 
against subtype 68a, while the detected infections were caused by the subtype 68b. 
Despite the decline of HPV DNA prevalence, anti-HPV antibodies are detectable in the 
populations at a more stable rate. Possible reasons for seroconversion to multiple HPV types 
include specific features of infection (exposures to multiple antigens), as well as biological 
properties of the host (certain women are more likely to elicit anti-HPV antibodies than the 
other females). Data supporting the hypothesis of a “good seroconverter” phenotype further 
appears in the study of anti-HPV antibody responses among the vaccinated (paper IV).  
6.2 HPV VACCINES INDUCE STABLY HIGH AND CROSS-REACTIVE ANTI-HPV ANTIBODY 
RESPONSES EVEN 12 YEARS AFTER IMMUNIZATION 
Anti-HPV antibody responses to vaccine-targeted HPV types 7-12 years from immunization 
are stably high in the BVR and the QVR  
A total of 92.3 % of QVR and 100 % of BVR had anti-HPV16 antibody levels above those 
induced after HPV infection. Anti-HPV18 seroprevalence was lower in the QVR compared to 
the BVR (81.9 % of vs 99.8 %, p <0.0001). Notably, 7 - 12 years post vaccination anti-HPV16 
and -18 antibody levels induced by each of the vaccines were stable and remained well above 
the median seropositivity levels of natural infection. The avidities of antibodies to vaccine-
targeted HPV types 16 and 18 were also higher in BVR. 
Anti-HPV-16 and HPV-18 antibody levels were substantially above the median anti-HPV 
antibody levels of natural infection: median anti-HPV-16 antibody levels were on average 14.8 
times higher among the QVR and 73.3 times higher among the BVR. Similar estimates for HPV-
18 were on average 5.1 and 80.0 times higher for the QVR and BVR, respectively.  
Throughout 7 - 12 years post vaccination, median antibody levels of both HR vaccine-targeted 
HPV types differed between bivalent and quadrivalent vaccines (average p-value <0.0001). 
Compared to QVR, recipients of Cervarix maintained on average 5.1 (HPV-16) and 18.4 (HPV-
18) times higher anti-HPV antibody levels.  
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As expected, seroprevalence of HPV-6 and -11 among the BVR were similar to those of 
unvaccinated individuals. Approximately ten years after vaccination, 91.7 % and 92.9 % of 
QVR, and 26.7 % and 14.1 % of BVR were seropositive to the vaccine-targeted low-risk HPV 
types. Antibody levels and avidity were also lower in the BVR. 
Bivalent and quadrivalent HPV vaccines induce broadly cross-reactive and long-lasting anti-
HPV antibody responses 
Seroprevalence to non-vaccine HPV types (HPV-31, -35, -45, -51, -52, -56, -58, and -68) were 
higher in the BVR than QVR. Compared to non-vaccinated females matched by age, 
seropositivity to non-vaccine HPV types was generally also higher among the vaccinated 
women. 
In both vaccine cohorts, seropositivity to non-vaccine types increases with increase in the 
HPV-16 antibody levels 
Women were grouped by the anti-HPV-16 antibody levels and by the vaccine type. Among 
the recipients of the bivalent HPV vaccine, anti-HPV-16 antibody levels and type-specific 
avidity to HPV-16 and -18 were elevated in the highest quartiles of anti-HPV-16 antibody 
levels (p<0.01). Likewise, antibody levels to the non-vaccine types 31, 35, 51, 52 and 58 were 
higher in the upper levels of anti-HPV-16 antibodies (p<0.01 for each one of these non-vaccine 
type). In a similar manner, seropositivity also increased with the anti-HPV-16 titer, most 
remarkably for types 31, 33, 35, 45, 51, 52, 58, 59, 68, and 73 (for each of these types: χ2 test 
p≤0.001). Levels of non-vaccine types HPV31, 35, 51, 52, 56 and 58 also increased in the upper 
quartiles of anti-HPV16 antibody levels. Antibody avidity did not differ across the strata of the 
anti-HPV-16 antibody titers. 
Among the recipients of the quadrivalent HPV vaccine, seroprevalence of the vaccine-
targeted types HPV-6, -11, -16 and -18 increased when grouped by the anti-HPV-16 antibody 
levels (test for trend in proportions p<0.001). In line with this, antibody levels of HPV-6, -11 
and -18 increased in the upper quartiles when compared to the lower strata of anti-HPV-16 
antibody levels (p<0.001 for each of the listed types). When compared to the lowest quartiles 
of anti-HPV16 antibody levels, anti-HPV-6, -11 and -16 antibody avidity increased in each 
subsequent anti-HPV-16 antibody level strata. This was the case also with the seroprevalence 
of the non-vaccine HPV types, most notably for HPV-31, -33, -35, -45, -52, -58, -59, and -68 
(for each of these HPV types: χ2 test p≤0.001). Levels of non-vaccine types did not increase in 
the upper quartiles of anti-HPV16 antibody levels when compared to the lowest. Like in the 
BVR, antibody avidity did not differ in the QVR across the strata of the anti-HPV16 antibody 
titers. 
Vaccine-induced seroprevalence, but not antibody levels and avidity, are higher in the BVR 
than in the QVR  
In all strata of anti-HPV-16 antibody levels, seroprevalence to HPV-31, -35 and -58 were higher 
in the BVR compared to the QVR (p <0.005 for each type). Proportions of vaccine recipients 
who were seropositive to HPV-45, -51 and -52 were also higher among the BVR than in the 
QVR but this was not consistent across the different strata of anti-HPV-16 antibody levels. In 
vaccine recipients with low (below median) anti-HPV-16 antibody levels, BVR had higher 
proportions of seropositive individuals than the QVR, most notably for HPV-31, -35, -52 and -
58 (p≤0.001 for each type). In vaccine recipients with high (above median) anti-HPV16 
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antibody levels, the seroprevalences to an even larger number of HPV types (p≤0.001 for -31, 
-35, -45, -51, -58; p=0.02 for HPV-52) were higher in the BVR than in the QVR.  
Anti-HPV16 antibody levels appeared to have little effect on differences in the antibody levels 
of the other HPV types across the vaccine recipient cohorts. Irrespectively of the anti-HPV16 
antibody strata, anti-HPV6/11 antibody prevalence, levels and avidity were higher among the 
QVR compared to BVR. 
Anti-HPV antibody levels in BVR detected shortly after HPV vaccination correlate with anti-
HPV antibody levels measured a decade later  
Anti-HPV antibody levels for vaccine types HPV-16 and -18 measured shortly after 
immunization, predicted antibody levels 7 - 12 years later. A subset of the BVR (N=96) were 
sampled also shortly after HPV vaccination, at seven-month interval (M7) after the first 
vaccine dose. This subset was stratified by the quartiles of the anti-HPV-16 and -18 antibody 
levels at M7. Antibody levels 7 - 12 years later were compared in the second, third and fourth 
quartiles vs the first quartile of M7 antibody level strata. BVR in the upper HPV-16 and -18 
quartiles, about ten years later had up to three-fold higher antibody levels to HPV-16 and -18, 
respectively, when compared to those in the lowest antibody quartiles (p <0.001). In a similar 
way, short-term antibody levels predicted avidity levels for HPV-16 (1.5 - 1.8 times higher, 
p≤0.01) but not for HPV-18. 
Summary 
In an independent, population-based setting, we followed-up women for up to twelve years 
from vaccination. We found that: (i) antibody levels induced by Cervarix were stable and even 
twelve years after vaccination virtually all women had anti-HPV antibody levels above those 
induced by the HPV infection; (ii) most of the women who were vaccinated with Gardasil had 
long-lasting stable anti-HPV antibody levels which, however, declined below the antibody 
level of natural infection in 8 % (HPV-16) and in 18 % (HPV-18) of the QVR; (iii) anti-HPV-16 
antibody levels were 5.1-fold higher and anti-HPV-18 were 18.4-fold higher in the BVR 
compared to QVR (p <0.0001). Also, (iv) seropositivity to most of the non-vaccine HPV types 
was more common among the BVR than the QVR; (v) anti-HPV antibody levels and avidity 
were comparable between the vaccines for almost all HPV types; (vi) vaccine-induced 
seroprevalence to HPV-31, -33, -35, -45, -52, -58, -59, -68 and -73 increased with anti-HPV-16 
levels; (vii) among the BVR, levels of non-vaccine types HPV-31, -35, -51, -52, -56 and -58 also 
increased in the upper quartiles of anti-HPV-16 levels; (viii) anti-HPV antibody levels at month 
7 predicted antibody levels 10 years later. 
Discussion 
In our study, 82 % of QVR had their anti-HPV-18 antibody levels above those which are 
acquired due to infection. Our findings of the cross-reactive antibody responses to HPV-31, -
33, -45, -52, and -58 are in line with those found in a slightly shorter follow-up study [118]. 
Compared to this similar study, we found lower proportions of women seropositive to the 
non-vaccine HPV types [118]. This might at least partially be explained by natural decline in 
the antibody levels over the long time. We also observed that seropositivity to HPV-52 and -
58 was more common among the BVR than among the QVR (p<0.001). Data on these two 
HPV types were inconsistent in previous reports and a meta-analysis resulted in no significant 
difference between the vaccines [122].  
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Our preliminary data using a neutralization assay are largely similar to the results observed 
with the current HPV antibody binding assay [120]. The few exceptions are higher 
seroprevalence of anti-HPV6 and anti-HPV33 antibodies in the neutralization assay. 
Otherwise, seroprevalence estimates for HPV types 31, 45, 52, and 58 measured with the 
neutralization assay were quite similar to those detected with our antibody binding assay. 
In our previous studies of anti-HPV antibody responses in the non-vaccinated cohort, some 
women appeared to seroconvert particularly well to HPV infections, suggesting that a high 
responder subgroup of women might exist [178]. Current findings in the vaccinated cohort 
support our earlier observations with the fact that women with higher anti-HPV antibody 
levels to vaccine-targeted HPV16 have also apparent higher seropositivity to almost all non-
vaccine HPV types at the same time, irrespectively of HPV vaccine used.  
Across the two vaccine recipient cohorts, serological signatures of anti-HPV antibody levels 
differed between the vaccines, such as only the BVR in the upper quartiles of anti-HPV-16 
antibody levels had higher titers to the non-vaccine types HPV-31, -35, -51, -52, -58 and -73 
compared to the group with the lowest anti-HPV-16 antibody levels. Our observation are in 
agreement with the short-term follow-up data on vaccine-targeted and cross-neutralizing 
types HPV-31, -33, -45, -52, and -58 published by others [117]. As in the neutralization assays, 
the cross-reactivity pattern was more pronounced among the BVR than the QVR.  
The main strengths of this study are its head-to-head comparison setting which allowed for a 
follow-up of anti-HPV antibody levels in a large cohort of vaccinated women (337 QVR and 
730 BVR) and for the longest so far reported interval (seven to twelve years after vaccination). 
Moreover, we used a validated anti-HPV antibody detection assay, which is independent of 
the vaccine antigens and comprise a wide panel of HPV types. We also evaluated anti-HPV 
antibody avidity and converted antibody levels into the International Units. The latter will 
facilitate future comparisons across the laboratories, methods and HPV types.  
There are, however, some limitations. Our vaccine recipient cohort was vaccinated at around 
17 years of age, which is higher than recommended and may in turn result in lower antibody 
levels as compared to vaccination at a younger age [132]. The cohorts differed in their sample 
size and number of participants had a skewed distribution over the follow-up years. There 
could have been a selection bias since only pregnant women entered the cohorts. In addition, 
participants of the PATRICIA vaccine trial were more represented than the FUTURE II (30.3 % 
vs 38.6 %; p<0.0001). Also, we do not know whether pregnancy affects serum antibody levels. 
Since the recipients of the two HPV vaccines were sampled in identical setting, it would not 
explain the serological differences observed between the cohorts of vaccinated women. 
Currently, clinical significance of seroreversion and of individual-level decline of anti-HPV 
antibody levels are under evaluation. Linkages to the healthcare registers will allow to identify 
almost all HPV-associated lesions that might have occurred among the vaccinated women. 
6.3 CERVICAL LESIONS AMONG WOMEN IMMUNIZED WITH HPV VACCINES ARE VERY 
RARELY ASSOCIATED WITH THE VACCINE-TARGETED HIGH-RISK HPV TYPES 
Study population  
According to the register-based data, 305,320 women have received ≥ 1 dose of HPV vaccine 
from its licensure in 2006 to 2014. Of these, 26 % attended cervical cancer screening program 
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in 2007-2016 and have had screening results reported to the NKCx. The following exclusion 
criteria were further applied to this cohort of women having been both HPV immunized and 
screened for cervical pathology: abnormal cytology test result or at least one referral to the 
biopsy prior to HPV vaccination, abnormal cytology that was not confirmed by histological 
testing, vaginal lesions, and other than CIN1 - 3 cervical diagnoses. In the remaining cohort 
(N=69,328), 3,576 women were diagnosed with CIN1 - 3. Irrespectively of cervical status, 
5,874 were vaccinated at young age (<17 years old) and resided in the greater Stockholm 
region (CIN1=179, CIN2=69, and CIN3=46) at the time of cervical screening. For these women, 
the number of vaccine doses was verified using data from the Swedish Prescribed Drug 
Register (National Board of Health and Welfare). 
Cervical samples (N=125: 84 CIN1, 25 CIN2, and 16 CIN3) of 42.5 % of all eligible CIN cases 
were identified at cytology biobank of the Karolinska University Laboratory. These were 
matched with eligible disease-free controls from the same cohort of women at a 1:2 ratio. 
Cryo-preserved cervical samples of interest were retrieved from the biobank, followed by 
DNA extraction, PCR and Luminex HPV typing. For sample quality reasons, four disease-free 
women were excluded from the statistical analysis. 
HPV prevalence among young vaccinated women differ from HPV DNA prevalence in the 
historical non-vaccinated cohort 
All samples (N=367) were negative for HPV-6 and -11. Compared to the population-based HPV 
DNA prevalence of vaccine-targeted types in the pre-vaccination time [199,200], we observed 
much lower HPV DNA positivity proportions in the HPV vaccinated young women. In the pre-
vaccination era about 38 % of CIN2+ lesions were HPV-16-positive, while in our study of the 
immunized cohort, none of samples from women with CIN2-3 contained HPV-16 DNA. 
However, a subset of the non-vaccine types (HPV-33, -51, -52, -56, -59, and -66) turned out to 
be more prevalent in the post-vaccination swabs. For example, HPV-39, -42, -68 and -90 
positivity (CIN1 only) was more common than in the pre-vaccination time. In women with 
CIN2-3, HPV-31, -35 and -45 were more prevalent among the vaccinated women than the 
historical nonvaccinated cohort. 
Association between HPV DNA positivity and development of cervical lesions in the young 
vaccinated women: pattern changes after introduction of HPV vaccination 
The pattern of HPV type-specific odds for development of CIN among young women also 
differed from that of the pre-vaccination time. In the young vaccinated women, HPV DNA 
positivity for types 45, 51 and 52 associated with the development of CIN2-3, while positivity 
for HPV-42, -51, -52, -56 and -66 associated with CIN1. HPV DNA positivity to certain HPV 
types, e.g., HPV-42, -51 and -66, tended to associate stronger with the presence of CIN1 in 
comparison to the pre-vaccination estimates. 
Summary 
We found that cervical lesions in women, vaccinated at <17 years of age, usually did not 
associate with the HPV types targeted by the HPV vaccine but rather with the non-vaccine 
HPV types.  
The main strengths of this study are its population-based design and the use healthcare 
register data to identify the HPV vaccinated women who have attended the cervical cancer 
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screening program and to trace the biobanked cervical smears of interest. We assessed 
cervical HPV DNA status in 42.5 % of all eligible samples from the HPV vaccinated young 
women who were diagnosed with CIN1 - 3 in the Stockholm region. Most of the diagnoses 
were revealed 2014 - 2016, when the screening coverage of the youngest age group was the 
highest across the other age groups. Moreover, HPV DNA was detected and typed by the HPV 
reference laboratory and using a well-established assay. The effect of HPV vaccination at a 
relatively young age was investigated within the subsequently detected cervical lesions when 
vaccine recipients attended their first cervical screening. By reducing our case-control cohort 
to the young recipients of HPV vaccines (<17 years at vaccination), we were aiming to limit 
the probability of exposure to HPV infection prior to vaccination. 
Of the main limitations of the study are its modest sample size of the cohort of cases, which 
prompted us for a combined analysis of the group of women who developed CIN2-3 with no 
further stratification by the risk of lesion progression. Another drawback is the 
representativeness: the biobank cohort was covering samples only from organized cervical 
screening, which does not start until women turn 23 years of age. This means that the samples 
taken at younger age out of the organized cervical screening program are not covered by this 
study. This, however, in our opinion makes the findings more generalizable to the overall 
female population.  
Population-level decline in HPV DNA prevalence [81,87,201] and cervical disease [159] were 
observed after introduction of HPV vaccination programmes. Compared to the historical 
cohort data in the Swedish population [201] and the pre-vaccination meta-analysis data [202], 
we now observed a remarkable reduction in HPV16/18 prevalence among the disease-free 
HPV vaccinated young women and those with cervical lesions. These findings are in 
agreement with vaccine effectiveness found in Scotland by monitoring of an immunization 
program that was based on the bivalent HPV vaccine showing that the prevalence of low-
grade cytological abnormalities was increasing with a concurrent decrease in detection of 
histological findings [159].  
The implications of our findings are that the neoplasms after HPV vaccination are most likely 
caused by those virus types which are not included in the HPV vaccine. This important 
limitation is important to communicate for preventing unjustified dissatisfaction with the HPV 
vaccines to vaccine producers, physicians but also women. However, yet another important 
message is that most of the HPV types, found in cervical lesions among the vaccinated 





The results of the presented studies contribute to our understanding of serological responses 
to HPV infections and vaccination, and can at least partially explain the nature of cervical 
lesions among young HPV-vaccinated women: 
In our studies of serological responses to HPV infection (paper I and II), HPV DNA strongly 
associated with the type-specific antibodies to HPV-16, -18, -31, -33, -35, -39, -45, -52, -56, -
58, and -59. Biological characteristics of serological responses were in agreement with those 
reported previously for HPV 16 [63]. In addition to these reports, we demonstrated that 
seropositivity to multiple anogenital HPVs, detectable in a sub-cohort of women, has specific 
biological characteristics as e.g. tendency to persist over time and strong association with past 
of current HPV infection, with abnormal cytology and with seroconversion to non-genital HPV 
types. Overall, our antibody detection against multiple HPV types was extensively validated 
in the non-vaccinated cohort and was thus found to be useful in the subsequent research 
projects on the humoral immune responses to HPV infection and HPV vaccination (papers III 
and IV).  
In our studies of vaccine-induced antibody responses we compared the two HPV vaccines in 
the head-to-head long-term follow-up settings. We demonstrated that even twelve years 
after immunization, most of the vaccinated women had detectable anti-HPV-16 and anti-HPV-
18 antibodies. The antibody levels were well above those induced by the HPV infection, as 
measured in our earlier studies. However, the antibody levels differed over time across the 
vaccine recipient cohorts in favor of the bivalent HPV vaccine as a notable fraction of the 
quadrivalent vaccine recipients lost measurable HPV-18 antibodies during follow-up. 
Nonetheless, both vaccines induced cross-reactive anti-HPV antibody responses and 
congruent with our previous observations in the non-vaccinated cohort, some HPV vaccinated 
women seroconvert particularly well. We further observed that cross-reactive HPV responses 
were more likely to occur in the vaccine recipients with high anti-HPV 16 antibody responses, 
which was more frequent in the bivalent vaccine recipients.  
The type-specific disease-protective threshold of anti-HPV antibodies is not known but 
essential for predicting vaccination success. In our next study (paper V), we thus focused on 
non-serological evaluation of the vaccine effectiveness against the clinical outcomes. 
We evaluated potential reasons for development of cervical lesions among young HPV 
vaccine recipients and found that cervical intraepithelial lesions among women having been 
HPV-vaccinated at a young age, are very rarely associated with the vaccine-targeted HPV 
types of high oncogenic risk. This has profound implications for the future design of cervical 
screening strategies that would target highly vaccinated cohorts of women and for design of 
surveillance and monitoring strategies, such as opting for less frequent screening starting at 
older age and monitoring effectiveness using more solid endpoints. Important public health 
message to the healthcare professionals and vaccinated populations is that cervical lesions 
may occur despite HPV vaccination. However, these neoplasms are likely caused by HPV types 




8 OPEN QUESTIONS 
Cervical cancer screening and HPV vaccination programs are walking hand-in-hand. That is 
why from the early time of HPV vaccine development it has been hypothesized that, should 
HPV vaccines prove efficacious, the introduction of HPV vaccination programs would demand 
modifications of the ongoing cervical cancer screening programs [26]. The need for this 
optimization is apparent today, in particular among the highly vaccinated cohorts [176], 
however a few questions closely related to the effectiveness of HPV vaccines remain 
unanswered. 
One of the most urgent issue is evaluation of a single-dose HPV vaccination regimen [136]. 
The need for this has been prompted by apparent win in the costs for vaccination and 
simplification of vaccine delivery, as well as by the emerging fear of HPV vaccine shortage 
after the WHO call towards the global elimination of cervical cancer. An additional question 
is whether all three HPV vaccines which are licensed to date would demonstrate non-
inferiority of the single-dose application. Should a single-dose vaccination demonstrate non-
inferiority to the two-dose schedule and become adopted in the routine vaccination practice, 
a continuous monitoring of effectiveness of the reduced-dose vaccination programs will be 
needed, where defined protective level of anti-HPV antibodies would increase effectiveness 
and speed of the surveillance. Global efforts in cervical cancer elimination accompanied by 
the efficient surveillance measures also require established international sera standards for 
all high-risk HPV types and at least two low risk genotypes (HPV-6 and -11) to allow for the 
direct comparison of the serology assays and for continuous control of their quality. 
Evaluation of protective anti-HPV antibody threshold not only against HPV infections but also 
against the clinical outcomes in needed. Searching for the protective level is challenging 
because cases of HPV-associated cervical disease among the HPV vaccinated women are 
uncommon, it usually takes several years to develop the lesion and, once occurring, the 
disease are mostly associated with the non-vaccine HPV types [164]. In vivo murine challenge 
models suggest that antibody protectivity levels could be at the limit of detection by the 
currently available serology assays [100]. On the other hand, anti-HPV antibody levels among 
the HPV-vaccinated HIV-infected subjects were shown to be almost identical in the 
breakthrough cases and in those women who remained protected [203], urging for search of 
additional correlates for more successful seroconversion and determinants for protection. 
Efficacy and effectiveness studies of HPV vaccines have demonstrated that a certain level of 
cross-protection against the phylogenetically related non-vaccine HPV types exists and that it 
differs across the HPV vaccines and HPV types [78,84,85,111]. We have observed that 
seroprevalence to the non-vaccine types increases with the anti-HPV antibody levels of the 
vaccine-targeted type. Once high titers of anti-HPV antibodies indeed confer better 
protection than responses with low levels of antibodies, evaluation of cross-protective 
potential of vaccine-targeted types would gain utmost practical importance. In addition, 
inferring from our findings that antibody levels as early as seven months from vaccination at 
least partially define anti-HPV antibody titers a decade later, evaluation of antibody level soon 
after vaccination with regard to protective potential decades later would be of clinical 
significance. 
The ongoing evaluations of HPV vaccine effectiveness take place in the populations with 
continued circulation of the papillomaviruses. Exposure to native antigens may stimulate 
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immune system in addition to the post-vaccination priming, thus may contribute towards 
maintenance of high levels of anti-HPV antibodies and broader cross-reactivity. However, it is 
yet unknown to which extend vaccine-induced antibody responses might be affected should 
the prevalence of circulating antigens approach zero. 
Detection of anti-HPV antibodies in the vaccinated individuals has mainly been performed in 
the serum samples and less commonly in the cervicovaginal secretions [92,94,95]. Both 
options are suboptimal when studying serological responses shortly after vaccination: blood 
withdrawal is invasive and cervicovaginal secretion sampling is not suitable for early 
adolescent girls. In contrast, detection of anti-HPV antibodies in oral mucosa would overcome 
these drawbacks, however currently available serology assays will require validation with a 
new sample type and probably with additional normalization against the total IgG or IgA 
levels. New findings will continuously refill the list of open questions, and with that I thank 
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